Germany · Delayed Price · Currency is EUR GeNeuro Company Description
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases.
The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials.
It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program.
In addition, the company has a collaborative development agreement with The National Institute of Neurological Disorders and Strokes for the development of an antibody program to block the activity of pHERV-K Env; and FondaMental Foundation for the development of diagnostic and therapeutic options for patients with Post-COVID neuropsychiatric syndromes, as well as research collaboration agreement with Northwestern University to confirm evidence of the expression of human endogenous retrovirus W envelope protein (W-ENV or W-ENV) in long-haul COVID patients; and US National Institute of Health for developing new approaches against pHERV-K (K-ENV) protein as a target in the treatment of amyotrophic lateral sclerosis.
GeNeuro SA was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
| Country | Switzerland |
| Founded | 2006 |
| Industry | Pharmaceutical Preparations |
| Employees | 17 |
| CEO | Jesus Martin-Garcia |
Contact Details
Address: 3 chemin du Pré-Fleur Plan-les-Ouates, 1228 Switzerland | |
| Phone | 41 22 552 48 00 |
| Website | geneuro.com |
Stock Details
| Ticker Symbol | GEM |
| Exchange | Frankfurt Stock Exchange |
| Share Class | Class C Shares |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jesus Martin-Garcia | Chief Executive Officer |
| Miguel Payró | Chief Financial Officer |